Wird geladen...

Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists

OBJECTIVE: Acute myeloid leukemia (AML) is primarily a disease of older adults. These patients may not be candidates for intensive treatment, and there has been an ongoing need for treatment options for this group. We review the use of glasdegib, a hedgehog-pathway inhibitor available for use in com...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Oncol Pharm Pract
Hauptverfasser: Relias, Valerie, McBride, Ali, Newman, Matthew J, Paul, Shilpa, Saneeymehri, Seyyedeh, Stanislaus, Genique, Tobin, Jennifer, Hoang, Caroline J, Ryan, Joanne C, Galinsky, Ilene
Format: Artigo
Sprache:Inglês
Veröffentlicht: SAGE Publications 2020
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8008421/
https://ncbi.nlm.nih.gov/pubmed/33215562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1078155220973737
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!